What Is the Life Expectancy of Someone With Sleep Apnea?

Untreated sleep apnea shortens life, but the size of the risk depends heavily on severity, age, sex, and whether you get treatment. One community-based study found that moderate-to-severe obstructive sleep apnea (OSA) was associated with a roughly sixfold increase in the risk of dying from any cause over the follow-up period, even after accounting for other health factors. That number is alarming, and the real picture is more layered than a single statistic can capture. The good news is that effective treatment appears to largely close the survival gap.

How Much Does Untreated Sleep Apnea Raise Mortality Risk?

Researchers have measured the link between sleep apnea and death in several large, long-running studies, and the signal is consistent: the more severe the apnea, the higher the mortality risk. In the Busselton Health Study, an Australian population-based cohort, people with moderate-to-severe OSA had a fully adjusted hazard ratio of 6.24 for all-cause mortality compared to those without OSA.¹ A large study of men with sleep apnea found that those with the highest breathing-disturbance scores who were also obese had the greatest mortality rate, and the risk climbed in a dose-response fashion: the worse the apnea, the worse the outcome.²

A 30-year prospective cohort study found that patients with severe, untreated OSA had significantly shorter survival than those with milder disease. When the researchers looked at patients using CPAP therapy, the survival gap between mild, moderate, and severe cases vanished entirely.³ That is a powerful finding: severity matters a great deal when the condition goes untreated, but with consistent treatment, those survival differences largely disappear.

No study provides a neat answer like “sleep apnea takes X years off your life,” because the risk depends on so many interacting factors. But the pattern across research is clear. Untreated moderate-to-severe sleep apnea roughly doubles to triples the risk of dying prematurely for most people, and in some populations, the risk is even higher.

Why Sleep Apnea Damages the Heart

The primary way sleep apnea kills is through the cardiovascular system. Every time your airway collapses during sleep, your blood oxygen drops and then spikes back up when breathing resumes. This cycle of low oxygen followed by reoxygenation, repeated dozens or even hundreds of times per night, triggers a cascade of damage. It generates reactive oxygen species that injure blood vessel walls, promotes chronic low-grade inflammation throughout the body, and accelerates atherosclerosis.⁴⁵ In untreated patients, this process plays out every hour of sleep, every night, over years or decades.

The consequences show up in hard outcomes. A landmark study in the New England Journal of Medicine found that OSA nearly doubled the adjusted risk of stroke or death: people with the condition had a hazard ratio of 1.97 for the combined endpoint of stroke or death from any cause, and the risk scaled with severity.⁶ Among older adults, those with severe OSA had about two and a half times the risk of suffering a stroke.⁷

Sleep apnea also disrupts heart rhythm. People with OSA are significantly more likely to develop atrial fibrillation, and if they already have it, the condition makes it harder to treat. A meta-analysis found that patients with OSA had a 25% greater risk of atrial fibrillation recurring after catheter ablation.⁸ In one study, patients with untreated OSA had an 82% recurrence rate of atrial fibrillation after cardioversion, compared to 42% in those whose OSA was treated with CPAP.⁹ Another study confirmed this pattern over longer follow-up: untreated sleep apnea was strongly associated with atrial fibrillation recurrence, with a hazard ratio of 2.79.¹⁰

Perhaps the most striking cardiovascular finding involves the timing of sudden cardiac death. In the general population, sudden cardiac death is least likely between midnight and 6 a.m. In people with OSA, the pattern is reversed: 46% of sudden cardiac deaths occurred during those overnight hours, compared to just 21% in people without OSA. The relative risk of sudden cardiac death during sleep hours was 2.57 for people with the condition.¹¹ The overnight hours, when apnea episodes are happening, are when these patients are most vulnerable.

How CPAP Changes the Survival Picture

Continuous positive airway pressure (CPAP) is the most studied treatment for sleep apnea, and the evidence consistently shows that it improves survival. In the 30-year cohort study mentioned earlier, patients who used CPAP for more than five years were 5.6 times more likely to survive than those who did not use CPAP at all. Even those who used it for five years or less were about three times more likely to survive than non-users.³

A French nationwide study of over 176,000 patients provided one of the starkest illustrations of what happens when people stop treatment. Over a three-year period, patients who discontinued CPAP had a significantly higher risk of death: the hazard ratio for continuing CPAP versus stopping was 0.61, meaning continuation was associated with roughly a 39% lower risk of dying. The benefit held for both men and women.¹² This study is particularly useful because its sheer size makes the findings hard to dismiss as a statistical fluke.

Consistency of use matters. In patients who also had chronic obstructive pulmonary disease, each additional hour of nightly CPAP use was associated with lower mortality risk.¹³ CPAP is not a once-in-a-while treatment. Its benefits accumulate with regular, long-term use.

How Age and Sex Change the Risk

One of the more counterintuitive findings in sleep apnea research is that the relative mortality risk from OSA appears to be highest in younger adults and actually decreases with age. A large study stratifying patients by age group found that compared to people without severe apnea, younger adults with severe OSA showed a modestly elevated mortality risk, while in middle-aged and older adults the adjusted odds ratio actually dropped below 1.0.¹⁴ A separate general population study confirmed this pattern: mild-to-moderate OSA significantly raised the risk of death in adults under 60 (hazard ratio of 1.59) but did not reach statistical significance in adults 60 and older.¹⁵

This does not mean sleep apnea becomes harmless in old age. Rather, competing causes of death become more dominant, and the relative contribution of sleep apnea to mortality shrinks against a background of higher baseline risk from other conditions. For a 40-year-old, untreated OSA might represent one of the most significant health threats they face. For an 80-year-old with heart disease, diabetes, and other conditions, sleep apnea is one risk factor among many.

Sex differences add another layer. One study found that proportionally more women with OSA died than men during follow-up, and the hazard of death was about 3.4 times greater for women than for men with OSA.¹⁶ A more recent nationwide analysis reinforced this: after adjusting for other health conditions, women with OSA had a 28% higher mortality risk compared to women without OSA, while men with OSA showed only a 3% increase that was not statistically significant.¹⁷ Women with sleep apnea may face a disproportionate burden partly because the condition is often recognized later in women, whose symptoms tend to be less “classic” than the loud snoring and witnessed apneas that prompt men to seek help.

Risks Beyond Cardiovascular Disease

Heart disease and stroke are the headline killers, but sleep apnea affects mortality through other channels too. The daytime sleepiness it causes raises accident risk. A systematic review and meta-analysis found that people with OSA have a clearly increased risk of motor vehicle crashes, with the crash-rate ratio likely falling between 1.2 and 4.9 depending on the population studied.¹⁸ A Danish nationwide cohort study confirmed an elevated risk of road traffic accidents, with motor vehicle accidents specifically about 29% more likely in the OSA group.¹⁹

The metabolic effects of OSA also compound risk. In women with type 2 diabetes, those who also had sleep apnea were significantly more insulin resistant and had higher predicted cardiovascular risk than women with diabetes alone.²⁰ Sleep apnea and metabolic disease feed each other in a cycle: OSA worsens insulin resistance, and the resulting weight gain worsens the apnea.

Cognitive decline is another growing concern. A meta-analysis found that people with sleep apnea had a 43% higher risk of developing dementia, including a 28% higher risk of Alzheimer’s disease and a 54% higher risk of Parkinson’s disease.²¹ The intermittent oxygen deprivation of OSA appears to promote the same brain changes seen in Alzheimer’s, including damage to the hippocampus. The encouraging aspect here is that some of this neurological damage appears to be at least partially reversible with treatment, suggesting OSA is a modifiable risk factor for cognitive decline.²²

Why the Standard Severity Score Can Be Misleading

If you have been diagnosed with sleep apnea, you were probably given a number called the apnea-hypopnea index, or AHI, which counts how many times per hour your breathing stops or becomes significantly shallow. It is the universal yardstick for classifying OSA as mild, moderate, or severe. The problem is that researchers are finding it is not a particularly good predictor of who will actually get sick or die.

The AHI counts events but does not capture how long each one lasts or how far your oxygen drops. Two people can have the same AHI but very different oxygen profiles: one might have brief, mild dips, while the other plunges to dangerously low levels for extended periods. Newer measures, collectively referred to as “hypoxic burden,” attempt to capture the depth and duration of oxygen drops rather than just their frequency. Studies have shown that these area-based measures are better at predicting cardiovascular disease and death than the AHI alone.²³ In the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study, hypoxic burden strongly predicted cardiovascular mortality, while AHI did not.²⁴

A related measure called ventilatory burden, which accounts for how hard the body has to work to restore normal breathing after each event, has also proven more predictive of cardiovascular and all-cause mortality than either AHI or hypoxic burden in some analyses.²⁵ The practical takeaway: if your AHI is “only mild,” that does not necessarily mean your risk is low, and if it is high, you might still have a relatively benign oxygen profile. These newer metrics are slowly making their way into clinical practice, but most sleep labs still rely primarily on the AHI.

Central Sleep Apnea and Heart Failure

Most of the mortality data discussed so far relates to obstructive sleep apnea, where the airway physically collapses. Central sleep apnea is a different condition in which the brain intermittently fails to send the right signals to the breathing muscles. It is far less common in the general population but shows up frequently in people with heart failure, where it carries its own mortality risk. Treatment of central sleep apnea in heart failure patients has been shown to improve heart function and transplant-free survival.²⁶ If you have heart failure and sleep apnea, the type of apnea matters for choosing the right treatment, and getting that diagnosis correct has real implications for survival.

Treatment Options Beyond CPAP

CPAP is effective, but adherence is a well-known problem. Many people find the mask uncomfortable, and inconsistent use undercuts the survival benefits. Fortunately, alternatives exist. Mandibular advancement devices, which are custom-fitted oral appliances that hold the lower jaw forward to keep the airway open, have shown durable effectiveness over a decade. A 10-year follow-up study found that both CPAP and mandibular advancement devices produced sustained reductions in breathing events and improvements in daytime functioning.²⁷ CPAP achieved a lower residual AHI at the end of the study, but both treatments kept the condition well-controlled. For people who cannot tolerate CPAP, an oral appliance is a meaningful alternative rather than going without treatment.

Weight loss remains one of the most impactful interventions for obstructive sleep apnea, since excess weight around the neck and abdomen directly contributes to airway collapse. Bariatric surgery provides the most dramatic example. A five-year prospective trial found that OSA was cured in about 55% of patients after gastric bypass surgery, with the average number of breathing events per hour dropping from roughly 28 to 9.²⁸ A Swedish study tracking outcomes over 20 years found that bariatric surgery was associated with a 32-percentage-point lower prevalence of OSA compared to usual care, and it also prevented new cases from developing.²⁹ That said, about one in five patients in the five-year study still had moderate or severe apnea after surgery, so weight loss does not guarantee a cure.

A newer and rapidly evolving area involves GLP-1 receptor agonist medications, originally developed for diabetes and now widely used for weight loss. Two separate meta-analyses found these drugs significantly reduced the AHI in people with OSA, with pooled reductions ranging from about 9.5 to roughly 14 fewer breathing events per hour compared to placebo.³⁰³¹ They also produced substantial weight loss and lowered blood pressure. Whether these medications can match CPAP’s long-term survival benefits is still unknown, but the early results suggest they address several of the mechanisms through which OSA increases mortality risk.

Sleep Apnea in Children

When people ask about life expectancy and sleep apnea, they usually picture a middle-aged or older adult. But sleep apnea in children has its own set of long-term consequences that can shape health trajectories for decades. A 20-year follow-up study found that young adults who had confirmed severe OSA in childhood had significantly higher body mass, fewer academic degrees, and more persistent snoring than controls, with childhood apnea severity trending toward predicting cardiovascular outcomes in adulthood.³² A 10-year multicenter study found that children with untreated OSA had higher risks of growth failure, delayed developmental milestones, obesity, and attention-deficit hyperactivity disorder, with these risks emerging early and persisting through follow-up.³³ The mortality risk for children is not the same as for adults, but untreated childhood OSA sets up metabolic, cognitive, and cardiovascular disadvantages that carry forward into adulthood. Getting it treated early, often with adenotonsillectomy, can prevent those cascading effects.